Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their first serious rival in China.
Suzhou-based Innovent Biologics Inc. secured approval last week for its treatment mazdutide, a turning point in China’s efforts to combat rising obesity and diabetes rates with local innovation. With over 600 million Chinese adults projected to be overweight by 2050, the emergence of a viable local alternative to Novo and Lilly’s blockbuster GLP-1 treatments could make weight loss drugs more accessible in the world’s second-largest economy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.